Sam Brusco, Associate Editor10.04.23
Paragonix Technologies, a pioneer in organ transplant solutions, has opened its new headquarters in Waltham, Mass. The company said the 34,000-square-foot center will be a consolidated hub for its diverse operations, equipped with state-of-the-art research and development labs and collaborative spaces.
The move follows Paragonix’s recent U.S. Food and Drug Administration (FDA) clearance for its BAROguard donor lung preservation system—the company’s fourth FDA-cleared device. The company said its products are located in over 120 transplant centers worldwide and have safeguarded over 4,000 donor organs.
“Witnessing the company’s evolution has been remarkable,” Paragonix’s CEO and co-founder Dr. Lisa Anderson told the press. “Paragonix was conceived with a vision to revolutionize organ transplantation through accessible, clinically-proven, and cost-effective technologies, in close collaboration with the clinical community. Today, we are thrilled to inaugurate our first major U.S. headquarters, a significant step forward in continuing our pioneering research and development efforts in transplant products and services. The facility will act as a hub for all contributors to our mission, enabling us to redefine standards of care and offer unparalleled support to the organ transplant community.”
The headquarters will also house support teams needed to extend the company’s national clinical and surgical services.
“The new headquarters will enable us to cater efficiently to the growing needs of our business and escalating demands of our clients,” said Paragonix’s senior VP of operations Garrett Riddle. “We are proud to facilitate this essential expansion, allowing Paragonix to develop innovative transplant solutions in a unified, dynamic environment.”
The move follows Paragonix’s recent U.S. Food and Drug Administration (FDA) clearance for its BAROguard donor lung preservation system—the company’s fourth FDA-cleared device. The company said its products are located in over 120 transplant centers worldwide and have safeguarded over 4,000 donor organs.
“Witnessing the company’s evolution has been remarkable,” Paragonix’s CEO and co-founder Dr. Lisa Anderson told the press. “Paragonix was conceived with a vision to revolutionize organ transplantation through accessible, clinically-proven, and cost-effective technologies, in close collaboration with the clinical community. Today, we are thrilled to inaugurate our first major U.S. headquarters, a significant step forward in continuing our pioneering research and development efforts in transplant products and services. The facility will act as a hub for all contributors to our mission, enabling us to redefine standards of care and offer unparalleled support to the organ transplant community.”
The headquarters will also house support teams needed to extend the company’s national clinical and surgical services.
“The new headquarters will enable us to cater efficiently to the growing needs of our business and escalating demands of our clients,” said Paragonix’s senior VP of operations Garrett Riddle. “We are proud to facilitate this essential expansion, allowing Paragonix to develop innovative transplant solutions in a unified, dynamic environment.”
